These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34526412)

  • 21. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery.
    Portilla D; Dent C; Sugaya T; Nagothu KK; Kundi I; Moore P; Noiri E; Devarajan P
    Kidney Int; 2008 Feb; 73(4):465-72. PubMed ID: 18094680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunction.
    Holzscheiter L; Beck C; Rutz S; Manuilova E; Domke I; Guder WG; Hofmann W
    Clin Chem Lab Med; 2014 Apr; 52(4):537-46. PubMed ID: 24243749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage.
    Yokoyama T; Kamijo-Ikemori A; Sugaya T; Hoshino S; Yasuda T; Kimura K
    Am J Pathol; 2009 Jun; 174(6):2096-106. PubMed ID: 19435794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urinary Liver-Type Fatty Acid-Binding Protein Predicts Residual Renal Function Decline in Patients on Peritoneal Dialysis.
    Torigoe K; Muta K; Tsuji K; Yamashita A; Ota Y; Kitamura M; Mukae H; Nishino T
    Med Sci Monit; 2020 Dec; 26():e928236. PubMed ID: 33347426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of renal function on serum and urinary heart fatty acid-binding protein levels.
    Nayashida N; Chihara S; Tayama E; Akasu K; Kai E; Kawara T; Aoyagi S
    J Cardiovasc Surg (Torino); 2001 Dec; 42(6):735-40. PubMed ID: 11698938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of a urinary biomarker panel for obstructive nephropathy and clinical outcomes.
    Xie Y; Xue W; Shao X; Che X; Xu W; Ni Z; Mou S
    PLoS One; 2014; 9(11):e112865. PubMed ID: 25402279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response of urinary liver-type fatty acid-binding protein to contrast media administration has a potential to predict one-year renal outcome in patients with ischemic heart disease.
    Fujita D; Takahashi M; Doi K; Abe M; Tazaki J; Kiyosue A; Myojo M; Ando J; Fujita H; Noiri E; Sugaya T; Hirata Y; Komuro I
    Heart Vessels; 2015 May; 30(3):296-303. PubMed ID: 24554034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules.
    Kamijo A; Sugaya T; Hikawa A; Okada M; Okumura F; Yamanouchi M; Honda A; Okabe M; Fujino T; Hirata Y; Omata M; Kaneko R; Fujii H; Fukamizu A; Kimura K
    Am J Pathol; 2004 Oct; 165(4):1243-55. PubMed ID: 15466390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary liver-type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone-induced acute kidney injury.
    Ohata K; Sugaya T; Nguyen HN; Arai K; Hatanaka Y; Uno K; Tohma M; Uechi T; Sekiguchi K; Oikawa T; Nagabukuro H; Kuniyeda K; Kamijo-Ikemori A; Suzuki-Kemuriyama N; Nakae D; Noiri E; Miyajima K
    Nephrology (Carlton); 2024 Mar; 29(3):117-125. PubMed ID: 37950597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of intravascular contrast media on urinary excretion of liver fatty acid-binding protein].
    Ohta S; Ishimitsu T; Minami J; Ono H; Matsuoka H
    Nihon Jinzo Gakkai Shi; 2005; 47(4):437-44. PubMed ID: 15971886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low levels of urinary liver-type fatty acid-binding protein may indicate a lack of kidney protection during aortic arch surgery requiring hypothermic circulatory arrest.
    Mori Y; Sato N; Kobayashi Y; Ochiai R
    J Clin Anesth; 2014 Mar; 26(2):118-24. PubMed ID: 24582841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic implications of urinary liver-type fatty acid-binding protein and 8-hydroxy-2'-deoxyguanosine in forensic autopsy cases.
    Kashiwagi M; Sugimura T; Matsusue A; Hara K; Waters B; Kubo S
    Leg Med (Tokyo); 2013 May; 15(3):140-4. PubMed ID: 23273867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical usefulness of urinary liver-type fatty-acid-binding protein as a perioperative marker of acute kidney injury in patients undergoing endovascular or open-abdominal aortic aneurysm repair.
    Obata Y; Kamijo-Ikemori A; Ichikawa D; Sugaya T; Kimura K; Shibagaki Y; Tateda T
    J Anesth; 2016 Feb; 30(1):89-99. PubMed ID: 26585768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urinary L-FABP as a marker of vesicoureteral reflux in children: could it also have a protective effect on the kidney?
    Benzer M; Tekin Neijmann S; Gültekin ND; Uluturk Tekin A
    Int Urol Nephrol; 2017 Jan; 49(1):1-12. PubMed ID: 27550232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical utility of urinary liver-type fatty acid binding protein measured by latex-enhanced turbidimetric immunoassay in chronic kidney disease.
    Kamijo-Ikemori A; Sugaya T; Yoshida M; Hoshino S; Akatsu S; Yamazaki S; Kimura K; Shibagaki Y
    Clin Chem Lab Med; 2016 Oct; 54(10):1645-54. PubMed ID: 26943609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urine liver fatty acid binding protein and chronic kidney disease progression.
    Khatir DS; Bendtsen MD; Birn H; Nørregaard R; Ivarsen P; Jespersen B; Buus NH
    Scand J Clin Lab Invest; 2017 Nov; 77(7):549-554. PubMed ID: 28745927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease.
    Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
    Am J Med Sci; 2005 Oct; 330(4):161-5. PubMed ID: 16234607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary L-FABP and its combination with urinary NGAL in early diagnosis of acute kidney injury after cardiac surgery in adult patients.
    Liu S; Che M; Xue S; Xie B; Zhu M; Lu R; Zhang W; Qian J; Yan Y
    Biomarkers; 2013 Feb; 18(1):95-101. PubMed ID: 23167703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary liver-type fatty acid binding protein is increased in the early stages of the disease with a risk of acute kidney injury induced by histone.
    Ohata K; Sugaya T; Nguyen HN; Hatanaka Y; Uno K; Tohma M; Oikawa T; Nagabukuro H; Kuniyeda K; Kamijo-Ikemori A; Suzuki-Kemuriyama N; Nakae D; Noiri E; Miyajima K
    Nephrology (Carlton); 2023 Jun; 28(6):345-355. PubMed ID: 37076661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary fatty acid binding protein in renal disease.
    Kamijo-Ikemori A; Sugaya T; Kimura K
    Clin Chim Acta; 2006 Dec; 374(1-2):1-7. PubMed ID: 16860300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.